Development of an expressive language sampling procedure in fragile x syndrome: A pilot study

Elizabeth Berry-Kravis, Emily Doll, Audra Sterling, Sara T. Kover, Susen M. Schroeder, Shaguna Mathur, Leonard Abbedut

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objective: There is a great need for valid outcome measures of functional improvement for impending clinical trials of targeted interventions for fragile X syndrome (FXS). Families often report conversational language improvement during clinical treatment, but no validated measures exist to quantify this outcome. This small-scale study sought to determine the feasibility, reproducibility, and clinical validity of highly structured expressive language sampling as an outcome measure reflecting language ability. Methods: Narrative and conversation tasks were administered to 36 verbal participants (25 males and 11 females) with FXS (aged 5-36 years, mean, 18 6 7 years). Alternate versions were used with randomized task order at 2- to 3-week intervals (mean, 19.6 6 6.4 days). Audio recordings of sessions were transcribed and analyzed. Dependent measures reflected talkativeness (total number of utterances), utterance planning (proportion of communication [C] units with mazes), articulation (proportion of unintelligible/partly unintelligible C-units), vocabulary (number of different word roots), and syntactic ability (mean length of utterance [MLU] in words). Reproducibility of measures was evaluated with intraclass correlation coefficients (ICC). Results: All participants could complete the tasks. Coded data were highly reproducible with Pearson's correlations at p < .01 for all measures and ICC values of .911 to .966 (conversation) and .728 to .940 (narration). Some measures including MLU and different word roots were correlated with expressive language subscale scores from the Vineland Adaptive Behavior Scale. Conclusions: These expressive language sampling tasks appear to be feasible, reproducible, and clinically valid and should be further validated in a larger cohort, as a promising means of assessing functional expressive language outcomes during clinical trials in FXS.

Original languageEnglish (US)
Pages (from-to)245-251
Number of pages7
JournalJournal of Developmental and Behavioral Pediatrics
Volume34
Issue number4
DOIs
StatePublished - May 1 2013

Fingerprint

Language Development
Language
Fragile X Syndrome
Aptitude
Articulation Disorders
Narration
Outcome Assessment (Health Care)
Clinical Trials
Vocabulary
Psychological Adaptation
Communication

Keywords

  • Autistic disorder
  • Expressive language
  • FMR1
  • Fragile X syndrome
  • Outcome measure

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Developmental and Educational Psychology
  • Psychiatry and Mental health

Cite this

Development of an expressive language sampling procedure in fragile x syndrome : A pilot study. / Berry-Kravis, Elizabeth; Doll, Emily; Sterling, Audra; Kover, Sara T.; Schroeder, Susen M.; Mathur, Shaguna; Abbedut, Leonard.

In: Journal of Developmental and Behavioral Pediatrics, Vol. 34, No. 4, 01.05.2013, p. 245-251.

Research output: Contribution to journalArticle

Berry-Kravis, Elizabeth ; Doll, Emily ; Sterling, Audra ; Kover, Sara T. ; Schroeder, Susen M. ; Mathur, Shaguna ; Abbedut, Leonard. / Development of an expressive language sampling procedure in fragile x syndrome : A pilot study. In: Journal of Developmental and Behavioral Pediatrics. 2013 ; Vol. 34, No. 4. pp. 245-251.
@article{711234d9177a402195730270b3573f43,
title = "Development of an expressive language sampling procedure in fragile x syndrome: A pilot study",
abstract = "Objective: There is a great need for valid outcome measures of functional improvement for impending clinical trials of targeted interventions for fragile X syndrome (FXS). Families often report conversational language improvement during clinical treatment, but no validated measures exist to quantify this outcome. This small-scale study sought to determine the feasibility, reproducibility, and clinical validity of highly structured expressive language sampling as an outcome measure reflecting language ability. Methods: Narrative and conversation tasks were administered to 36 verbal participants (25 males and 11 females) with FXS (aged 5-36 years, mean, 18 6 7 years). Alternate versions were used with randomized task order at 2- to 3-week intervals (mean, 19.6 6 6.4 days). Audio recordings of sessions were transcribed and analyzed. Dependent measures reflected talkativeness (total number of utterances), utterance planning (proportion of communication [C] units with mazes), articulation (proportion of unintelligible/partly unintelligible C-units), vocabulary (number of different word roots), and syntactic ability (mean length of utterance [MLU] in words). Reproducibility of measures was evaluated with intraclass correlation coefficients (ICC). Results: All participants could complete the tasks. Coded data were highly reproducible with Pearson's correlations at p < .01 for all measures and ICC values of .911 to .966 (conversation) and .728 to .940 (narration). Some measures including MLU and different word roots were correlated with expressive language subscale scores from the Vineland Adaptive Behavior Scale. Conclusions: These expressive language sampling tasks appear to be feasible, reproducible, and clinically valid and should be further validated in a larger cohort, as a promising means of assessing functional expressive language outcomes during clinical trials in FXS.",
keywords = "Autistic disorder, Expressive language, FMR1, Fragile X syndrome, Outcome measure",
author = "Elizabeth Berry-Kravis and Emily Doll and Audra Sterling and Kover, {Sara T.} and Schroeder, {Susen M.} and Shaguna Mathur and Leonard Abbedut",
year = "2013",
month = "5",
day = "1",
doi = "10.1097/DBP.0b013e31828742fc",
language = "English (US)",
volume = "34",
pages = "245--251",
journal = "Journal of Developmental and Behavioral Pediatrics",
issn = "0196-206X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Development of an expressive language sampling procedure in fragile x syndrome

T2 - A pilot study

AU - Berry-Kravis, Elizabeth

AU - Doll, Emily

AU - Sterling, Audra

AU - Kover, Sara T.

AU - Schroeder, Susen M.

AU - Mathur, Shaguna

AU - Abbedut, Leonard

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Objective: There is a great need for valid outcome measures of functional improvement for impending clinical trials of targeted interventions for fragile X syndrome (FXS). Families often report conversational language improvement during clinical treatment, but no validated measures exist to quantify this outcome. This small-scale study sought to determine the feasibility, reproducibility, and clinical validity of highly structured expressive language sampling as an outcome measure reflecting language ability. Methods: Narrative and conversation tasks were administered to 36 verbal participants (25 males and 11 females) with FXS (aged 5-36 years, mean, 18 6 7 years). Alternate versions were used with randomized task order at 2- to 3-week intervals (mean, 19.6 6 6.4 days). Audio recordings of sessions were transcribed and analyzed. Dependent measures reflected talkativeness (total number of utterances), utterance planning (proportion of communication [C] units with mazes), articulation (proportion of unintelligible/partly unintelligible C-units), vocabulary (number of different word roots), and syntactic ability (mean length of utterance [MLU] in words). Reproducibility of measures was evaluated with intraclass correlation coefficients (ICC). Results: All participants could complete the tasks. Coded data were highly reproducible with Pearson's correlations at p < .01 for all measures and ICC values of .911 to .966 (conversation) and .728 to .940 (narration). Some measures including MLU and different word roots were correlated with expressive language subscale scores from the Vineland Adaptive Behavior Scale. Conclusions: These expressive language sampling tasks appear to be feasible, reproducible, and clinically valid and should be further validated in a larger cohort, as a promising means of assessing functional expressive language outcomes during clinical trials in FXS.

AB - Objective: There is a great need for valid outcome measures of functional improvement for impending clinical trials of targeted interventions for fragile X syndrome (FXS). Families often report conversational language improvement during clinical treatment, but no validated measures exist to quantify this outcome. This small-scale study sought to determine the feasibility, reproducibility, and clinical validity of highly structured expressive language sampling as an outcome measure reflecting language ability. Methods: Narrative and conversation tasks were administered to 36 verbal participants (25 males and 11 females) with FXS (aged 5-36 years, mean, 18 6 7 years). Alternate versions were used with randomized task order at 2- to 3-week intervals (mean, 19.6 6 6.4 days). Audio recordings of sessions were transcribed and analyzed. Dependent measures reflected talkativeness (total number of utterances), utterance planning (proportion of communication [C] units with mazes), articulation (proportion of unintelligible/partly unintelligible C-units), vocabulary (number of different word roots), and syntactic ability (mean length of utterance [MLU] in words). Reproducibility of measures was evaluated with intraclass correlation coefficients (ICC). Results: All participants could complete the tasks. Coded data were highly reproducible with Pearson's correlations at p < .01 for all measures and ICC values of .911 to .966 (conversation) and .728 to .940 (narration). Some measures including MLU and different word roots were correlated with expressive language subscale scores from the Vineland Adaptive Behavior Scale. Conclusions: These expressive language sampling tasks appear to be feasible, reproducible, and clinically valid and should be further validated in a larger cohort, as a promising means of assessing functional expressive language outcomes during clinical trials in FXS.

KW - Autistic disorder

KW - Expressive language

KW - FMR1

KW - Fragile X syndrome

KW - Outcome measure

UR - http://www.scopus.com/inward/record.url?scp=84880062089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880062089&partnerID=8YFLogxK

U2 - 10.1097/DBP.0b013e31828742fc

DO - 10.1097/DBP.0b013e31828742fc

M3 - Article

C2 - 23669871

AN - SCOPUS:84880062089

VL - 34

SP - 245

EP - 251

JO - Journal of Developmental and Behavioral Pediatrics

JF - Journal of Developmental and Behavioral Pediatrics

SN - 0196-206X

IS - 4

ER -